Digest Network Come funziona
Network
/
Società
Mi
Non verificato

Mirum Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieMercato azionarioSalute

57 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Biotecnologia
Farmaceutica
Salute
Mercato azionario
Finanza
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Eventi
Industria
Pubblico Esercizio/Vendita al dettaglio
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Web e Social Network
Fiere
Eventi
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
19/12/2025
Biotecnologia
Salute
Scienza
Farmaceutica
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/12/2025
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/12/2025
Mercato azionario
Web e Social Network
Telefonia e Varie
Finanza
Industria
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/12/2025
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/11/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/11/2025
Mercato del lavoro
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/11/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0